Professor Stalmans said: ‘Amakem is a relatively young organization to sponsor a Seat at a respected University and it is a way of measuring the maturity of their approach. As a member of the Amakem Clinical Advisory Board, I have experienced the chance to work carefully with them because they have advanced AMA0076 into the clinic as an extremely promising brand-new treatment for glaucoma and ocular hypertension. I am grateful for the chance presented by the Chair to advance work in to the technology underlying glaucoma and various other diseases and look forward to this function being translated into fresh medicines.’ Related StoriesAAO announces start of new online source to improve eye look after childrenStudy: Programmable electronic glasses help improve vision in children identified as having lazy eyeGood information for patients experiencing dry age-related macular degeneration The KU Leuven Seat sponsorship is intended to further fundamental analysis and the Seat holder is certainly appointed by the Rector of the University on the recommendation of the Dean of the relevant faculty.Consequently, elucidating the pathology of the endocannabinoid program during neuroinflammation and neurodegeneration might open up fresh avenues of therapeutic interventions later on. .

CVS Caremark net revenues boost 1. Second Quarter Year-over-calendar year Highlights: Operating profit elevated 15.2 percent to approximately $2.0 billion Adjusted EPS improved 19.6 percent to $0.97; GAAP diluted EPS from continuing operations increased 20.8 percent to $0.91 Retail pharmacy same shop prescription volumes elevated 1.8 percent, or 5.0 percent on a 30-day equivalent basis Retail pharmacy same shop sales elevated 0.8 percent; total same store sales improved 0.4 percent Year-to-time Highlights: Generated free cashflow of $1.7 billion Cashflow from operations of $2.5 billion 2013 Assistance: Narrowed 2013 full-year Adjusted EPS range to $3.90 to $3.96 and GAAP diluted EPS from continuing operations range to $3.65 to $3.71 Provided third quarter Adjusted EPS guidance of $1.00 to $1.03 and GAAP diluted EPS from continuing operations assistance of $0.94 to $0.97 Expect full year free cashflow of $4.8 to $5.1 billion and cash flow from operations of $6.4 to $6.